mRNA cancer vaccine clears a melanoma Phase 3 test
Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value.
The 60-second version
Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value.
Key points
- The vaccine is designed from each tumor’s molecular features.
- The trial measured recurrence-free and distant-metastasis-free survival.
- A company-announced positive result is not proof that every patient is cured.
Verdict. This is a strong signal for personalized vaccines, not a cure headline.
What changedmRNA cancer vaccine clears a melanoma Phase 3 test
Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value.
Why it mattersThe vaccine is designed from each tumor’s molecular features.
Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value. The vaccine is designed from each tumor’s molecular features. This is a strong signal for personalized vaccines, not a cure headline.
Why it mattersThe trial measured recurrence-free and distant-metastasis-free survival.
Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value. The trial measured recurrence-free and distant-metastasis-free survival. This is a strong signal for personalized vaccines, not a cure headline.
Why it mattersA company-announced positive result is not proof that every patient is cured.
Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value. A company-announced positive result is not proof that every patient is cured. This is a strong signal for personalized vaccines, not a cure headline.
This is a strong signal for personalized vaccines, not a cure headline.